Condition: Advanced/Metastatic Solid Tumors · NSCLC · Sponsor: Shanghai Henlius Biotech
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX37 in patients with advanced/metastatic solid tumors.
This description comes directly from the study's public registry record.
Liya Wan · 86+13911662820 · Liya_Wan@henlius.com
Tianqing Chu · 021-22200000
Always discuss trial participation with your own doctor first.
| Shanghai Chest Hospital | Shanghai, China | Recruiting |
| The Second Affiliated Hospital of Air Force Medical University of the People's Liberation Army of China | Xi'an, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07274813